Our products

Ticagrelor

CAS No.

274693-27-5

Reference product

BRILINTA, BRILIQUE/AstraZeneca

Polymorphic form

Form II

Therapeutic Area

Blood & blood forming organs

Status

pipeline

EU DMF readiness

US DMF readiness

028674

CEP

Pending

Other documentation

Canadian DMF
Brazilian DMF

Drug description:

Ticagrelor is an antiplatelet agent.
Ticagrelor co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
It is formulated as tablets, film-coated tablets for oral route of administration.

Mechanism of action:

Ticagrelor is a platelet ADP P2Y12 receptor antagonist. It helps to prevent the formation of blood clots and reduces the occurrence of thrombotic events in acute coronary syndromes (ACS). ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes. The drug candidate is also acts by preventing adenosine from being cleared from the blood stream and by marginally increasing the levels of immune cell activity.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.
Polpharma’s strategic investment in HPAPI facility
We have launched an investment in a specialized facility
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).

The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.

LEARN MORE